Companies / Health Care
AMGN
Amgen
Biotechnology
BiotechnologyAnalysis in progress
In progress
We are decoding this company's strategy and relationships
New analyses are published every weekday. Founding members get them first.
Business at a glance
Operating-health scores describe reported fundamentals on a 0–100 scale. They are not a rating of the stock. How they work
Operating health66
Growth61
Profitability82
Cash generation87
Balance sheet24
Dilution control75
Key ratios and five-year financials
Latest quarter revenue YoY (2026-09-30)8.5%Revenue growth (FY)10.0%Revenue CAGR (3y)11.8%Gross margin67.2%Operating margin24.7%Net margin21.0%Free cash flow margin22.0%R&D / revenue19.8%Stock comp / revenue1.3%Net debt / operating cash flow5.03xCurrent ratio1.14Diluted share count change0.2%
| Fiscal year ending | FY 2021-12 | FY 2022-12 | FY 2023-12 | FY 2024-12 | FY 2025-12 |
|---|---|---|---|---|---|
| Revenue | $26.0B | $26.3B | $28.2B | $33.4B | $36.8B |
| Gross profit | $19.5B | $19.9B | $19.7B | $20.6B | $24.7B |
| Operating income | $7.6B | $9.6B | $7.9B | $7.3B | $9.1B |
| Net income | $5.9B | $6.6B | $6.7B | $4.1B | $7.7B |
| Operating cash flow | $9.3B | $9.7B | $8.5B | $11.5B | $10.0B |
| Capital expenditure | $880M | $936M | $1.1B | $1.1B | $1.9B |
| Free cash flow | $8.4B | $8.8B | $7.4B | $10.4B | $8.1B |
| R&D | $4.8B | $4.4B | $4.8B | $6.0B | $7.3B |
| Stock-based comp | $341M | $401M | $431M | $530M | $494M |
| Buybacks | $5.0B | $6.4B | $0 | $200M | $0 |
| Dividends | $4.0B | $4.2B | $4.6B | $4.8B | $5.1B |
| Cash | $8.0B | $7.6B | $10.9B | $12.0B | $9.1B |
| Total debt | $33.4B | $40.5B | $66.1B | $63.6B | $59.2B |
| Equity | $6.7B | $3.7B | $6.2B | $5.9B | $8.7B |
StratGraph publishes general, impersonal research about public companies based on public filings. It is not investment advice, not a recommendation to buy, sell or hold any security, and not tailored to any reader's circumstances. Content may contain errors and may be partly generated with AI tools; verify against the original filings, which are linked. Authors may not trade securities discussed within the window set by our trading policy. Full disclaimer.